SLN
Silence Therapeutics plc
NASDAQ · GBHealthcareBiotechnology
$10.49-0.10%
Price as of Jul 20, 2026
SLN profitability
Silence Therapeutics plc profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 66.4%
- EBITDA margin
- -8478.5%
- EBIT margin
- -9396.6%
- Net margin
- -9243.0%
- Free cash flow margin
- -7126.6%
Returns
- Return on equity
- -172.4%
- Return on assets
- -74.0%
- Return on invested capital
- -174.8%
- Asset turnover
- 0.01x
Cash efficiency
- Cash from operations
- -$65.6M
- Cash per share
- $1.48
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.